COMP360 synthetic psilocybin treatment
Search documents
 NeuroKaire Enters into R&D Collaboration with Compass Pathways to Pioneer Precision Treatments for Depression
 Prnewswire· 2025-10-30 12:30
Accessibility StatementSkip Navigation Collaboration will leverage AI-powered neural analysis and Compass' expertise in psychedelic drug development to advance new therapies for mental health KEARNY, N.J., Oct. 30, 2025 /PRNewswire/ -- NeuroKaire, a pioneer in precision psychiatry and neurology, has launched an R&D collaboration with Compass Pathways, a leading biotechnology company dedicated to transforming mental health care. This collaboration aims to deepen the mechanistic understanding of psychedelic c ...
 Compass Pathways Appoints Dr. Jeffrey Jonas to Board of Directors
 Businesswire· 2025-10-29 10:30
Oct 29, 2025 6:30 AM Eastern Daylight Time Compass Pathways Appoints Dr. Jeffrey Jonas to Board of Directors Share LONDON & NEW YORK--(BUSINESS WIRE)--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, today announced the appointment of Dr. Jeffrey Jonas to its Board of Directors, effective immediately. Dr. Jonas brings more than three decades of leadership in pharmaceutical research and development, with a par ...